Haemonetics price target lowered to $90 from $115 at Mizuho

Mizuho lowered the firm’s price target on Haemonetics (HAE) to $90 from $115 and keeps an Outperform rating on the shares post the earnings report. The firm says the story is in an “air-pocket reset mode across” as it brought estimates down for the core Plasma and Hospital segments. However, it still sees potential near-term re-rate potential for the shares.